Table 1 Demographic, clinical, genetic and radiographic characteristics of African American participants with RA and healthy controls from the CLEAR registry.
| Â | Cases | Controls | ||
|---|---|---|---|---|
Baseline characteristics | CLEAR I N = 233 | CLEAR II N = 360 | CLEAR I N = 139 | CLEAR II N = 265 |
Age in years, mean (SE) | 50.0 (13.0) | 56.0 (11.8) | 48.1 (12.4) | 57.3 (8.7) |
Sex (female), % | 82.7 | 85.0 | 75.5 | 72.0 |
Disease duration in months, mean (SE) | 12.9 (7.1) | 114.0 (119.2) | - | - |
Body mass index, mean (SE) | 31.4 (7.8) | - | 31.7 (7.6) | - |
Global European admixture estimate, mean (SE) | 0.17 (0.09) | 0.16 (0.10) | 0.16 (0.09) | 0.17 (0.10) |
Number of tender joints, median (IQR 25–75) | 4.0 (1.0–12.0) | 4.0 (1.0–9.5) | - | - |
Number of swollen joints, median (IQR 25–75) | 3.0 (1.0–7.0) | 4.0 (1.0–10.0) | - | - |
Medications | Â | Â | Â | Â |
Biologics ever used (%) | 4.4 | - | 19.5 | - |
Other DMARDs (%) | 81.4 | - | 87.1 | - |
Methotrexate, current use (%) | 63.9 | 60.3 | - | - |
Radiographic score, mean (SE) | Â | Â | Â | Â |
Joint-erosion score | 1.6 (4.3) | 10.7 (18.5) | Â | Â |
Joint-narrowing score | 2.1 (5.7) | 18.1 (27.7) | Â | Â |
Total score | 3.7 (9.4) | 28.8 (44.1) | Â | Â |